🇺🇸 FDA
Patent

US 9074213

Compositions and methods for inhibiting expression of a target gene

granted A61KA61K38/00A61P

Quick answer

US patent 9074213 (Compositions and methods for inhibiting expression of a target gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61P, A61P25/28, A61P31/12